TransMedics Group, Inc. (NASDAQ:TMDX) Receives $133.88 Average Price Target from Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been assigned an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $133.88.

A number of research firms recently issued reports on TMDX. Oppenheimer lifted their target price on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Stephens began coverage on TransMedics Group in a research note on Tuesday, June 4th. They set an “overweight” rating and a $151.00 price objective on the stock. TD Cowen raised their price objective on TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Cantor Fitzgerald began coverage on TransMedics Group in a research note on Thursday, June 6th. They set an “overweight” rating and a $161.00 price objective on the stock. Finally, Canaccord Genuity Group raised their price objective on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st.

TransMedics Group Stock Performance

TMDX stock opened at $149.53 on Tuesday. The business’s 50-day moving average price is $135.87 and its two-hundred day moving average price is $101.27. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The firm has a market cap of $4.93 billion, a PE ratio of -439.79 and a beta of 1.98. TransMedics Group has a 1-year low of $36.42 and a 1-year high of $154.14.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. The company had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The company’s quarterly revenue was up 132.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.08) earnings per share. As a group, research analysts forecast that TransMedics Group will post 0.77 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 15,512 shares of the firm’s stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $90.45, for a total transaction of $1,403,060.40. Following the completion of the transaction, the insider now directly owns 25,185 shares of the company’s stock, valued at approximately $2,277,983.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CEO Waleed H. Hassanein sold 12,000 shares of TransMedics Group stock in a transaction dated Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the transaction, the chief executive officer now directly owns 74,087 shares of the company’s stock, valued at approximately $7,044,932.83. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 15,512 shares of TransMedics Group stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $90.45, for a total value of $1,403,060.40. Following the completion of the transaction, the insider now directly owns 25,185 shares of the company’s stock, valued at $2,277,983.25. The disclosure for this sale can be found here. Insiders sold a total of 270,554 shares of company stock valued at $31,760,498 in the last three months. Insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TMDX. Pitcairn Co. boosted its stake in TransMedics Group by 1.5% during the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock valued at $398,000 after purchasing an additional 78 shares during the last quarter. Harbour Capital Advisors LLC boosted its stake in TransMedics Group by 1.7% during the 4th quarter. Harbour Capital Advisors LLC now owns 8,371 shares of the company’s stock valued at $627,000 after purchasing an additional 140 shares during the last quarter. RiverPark Advisors LLC boosted its stake in TransMedics Group by 19.5% during the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after purchasing an additional 215 shares during the last quarter. First Horizon Advisors Inc. boosted its stake in TransMedics Group by 26.8% during the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its stake in TransMedics Group by 3.4% during the 1st quarter. Park Avenue Securities LLC now owns 11,374 shares of the company’s stock valued at $841,000 after purchasing an additional 372 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.